Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY-NC-ND 4.0ESMO Open

Efficacy of immediate radiotherapy versus salvage radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma responsive to chemoimmunotherapy

  • Q.-T. Zhang1,2
  • J.-R. He3
  • H.-B. Guo1,2
  • Y.-N. Sun1,2
  • J. Chen1,2
  • H. Cheng1,2
  • Y.-X. Xiao1,2
  • X.-S. Sun1,2
  • L.-F. Wu1,2
  • X.-Y. Li1,2
  • Q.-Y. Chen1,2
  • L.-Q. Tang1,2
2 more authors
  • H.-Q. Mai1,2
  • L.-T. Liu1,2
  1. 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
  2. 2Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
  3. 3Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China
Read full textPDFDOICite

Abstract

Background: Chemoimmunotherapy has become the standard first-line treatment for de novo metastatic nasopharyngeal carcinoma (dmNPC). However, the role and optimal timing of locoregional radiotherapy in dmNPC in the chemoimmunotherapy era remain unclear. This study aims to evaluate whether salvage locoregional radiotherapy (SLRRT), deferred until locoregional progression in patients with well-controlled distant metastases, compromises survival compared with immediate locoregional radiotherapy (ILRRT) in responders to first-line chemoimmunotherapy.

Patients and methods: This retrospective cohort study included consecutive patients with dmNPC who achieved a complete or partial response after first-line platinum-based chemotherapy combined with anti-programmed cell death protein 1 therapy. The primary endpoint was overall survival (OS). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline characteristics. Survival outcomes were assessed using Kaplan–Meier analyses and a multivariate Cox regression model.

Results: A total of 439 patients were included, with a median follow-up of 35.0 months (interquartile range, 24.0-45.2). Of these, 331 patients were assigned to the ILRRT cohort and 108 to the SLRRT cohort. After IPTW adjustment, SLRRT was not associated with inferior OS compared with ILRRT [2-year OS, 97.4% versus 90.1%; hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.54-1.59, P = 0.78]. SLRRT was associated with worse locoregional control (HR 4.78, 95% CI 2.98-7.66, P < 0.001) but better distant control (HR 0.62, 95% CI 0.41-0.95, P = 0.03). Radiotherapy-related adverse effects were substantially more frequent in the ILRRT cohort.

Conclusions: Deferring SLRRT until locoregional progression did not compromise survival among responders to first-line chemoimmunotherapy. These findings support a response-adapted, de-escalated treatment strategy that may reduce treatment-related toxicities and improve quality of life without adversely affecting survival.

Related

  1. Estimating Individualized Survival Benefit of Consolidative Metastasis-Directed Radiotherapy Following Chemoimmunotherapy in Nasopharyngeal Carcinoma With Exclusive Distant Metastasis.
    Xuguang Wang, Shuwei Chen, Xing Zhang +11
    MedCommPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Development and validation of a metabolic syndrome-based nomogram to predict 1-year metastasis after radiotherapy in locally advanced nasopharyngeal carcinoma
    Yanyu Chen, Hao Cheng, Changjun Xie +10
    Annals of medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Postoperative radiotherapy versus systemic therapy alone for locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy
    Zongqian Yuan, Junfeng Zhao, Chunhui Li +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiers
  4. Radiomics-driven multimodal integration in precision radiotherapy for nasopharyngeal carcinoma— current evidence, clinical barriers, and future directions
    Yuhan Ma, Yuxin Xie, Qitao Gou +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  5. Hyaluronic acid-based osmolality-responsive immediate-release microneedles co-loading baicalein and astaxanthin for oral ulcer therapy.
    Jinfan Yang, Kaihong Shi, Jiachen Wang +9
    Materials today. BioPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{zhang2026efficacy,
  title = {{Efficacy of immediate radiotherapy versus salvage radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma responsive to chemoimmunotherapy}},
  author = {Q.-T. Zhang and J.-R. He and H.-B. Guo and Y.-N. Sun and J. Chen and H. Cheng and Y.-X. Xiao and X.-S. Sun and L.-F. Wu and X.-Y. Li and Q.-Y. Chen and L.-Q. Tang and H.-Q. Mai and L.-T. Liu},
  journal = {ESMO Open},
  year = {2026},
  month = oct,
  doi = {10.1016/j.esmoop.2026.108608},
  url = {https://doi.org/10.1016/j.esmoop.2026.108608},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Efficacy of immediate radiotherapy versus salvage radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma responsive to chemoimmunotherapy
AU  - Q.-T. Zhang
AU  - J.-R. He
AU  - H.-B. Guo
AU  - Y.-N. Sun
AU  - J. Chen
AU  - H. Cheng
AU  - Y.-X. Xiao
AU  - X.-S. Sun
AU  - L.-F. Wu
AU  - X.-Y. Li
AU  - Q.-Y. Chen
AU  - L.-Q. Tang
AU  - H.-Q. Mai
AU  - L.-T. Liu
PY  - 2026
DA  - 2026/10/30
JO  - ESMO Open
DO  - 10.1016/j.esmoop.2026.108608
UR  - https://doi.org/10.1016/j.esmoop.2026.108608
AB  - Background: Chemoimmunotherapy has become the standard first-line treatment for de novo metastatic nasopharyngeal carcinoma (dmNPC). However, the role and optimal timing of locoregional radiotherapy in dmNPC in the chemoimmunotherapy era remain unclear. This study aims to evaluate whether salvage locoregional radiotherapy (SLRRT), deferred until locoregional progression in patients with well-controlled distant metastases, compromises survival compared with immediate locoregional radiotherapy (ILRRT) in responders to first-line chemoimmunotherapy.  Patients and methods: This retrospective cohort study included consecutive patients with dmNPC who achieved a complete or partial response after first-line platinum-based chemotherapy combined with anti-programmed cell death protein 1 therapy. The primary endpoint was overall survival (OS). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline characteristics. Survival outcomes were assessed using Kaplan–Meier analyses and a multivariate Cox regression model.  Results: A total of 439 patients were included, with a median follow-up of 35.0 months (interquartile range, 24.0-45.2). Of these, 331 patients were assigned to the ILRRT cohort and 108 to the SLRRT cohort. After IPTW adjustment, SLRRT was not associated with inferior OS compared with ILRRT [2-year OS, 97.4% versus 90.1%; hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.54-1.59, P = 0.78]. SLRRT was associated with worse locoregional control (HR 4.78, 95% CI 2.98-7.66, P < 0.001) but better distant control (HR 0.62, 95% CI 0.41-0.95, P = 0.03). Radiotherapy-related adverse effects were substantially more frequent in the ILRRT cohort.  Conclusions: Deferring SLRRT until locoregional progression did not compromise survival among responders to first-line chemoimmunotherapy. These findings support a response-adapted, de-escalated treatment strategy that may reduce treatment-related toxicities and improve quality of life without adversely affecting survival.
SN  - 2059-7029
ER  -